<DOC>
	<DOCNO>NCT01924845</DOCNO>
	<brief_summary>Study 701-301 single-arm , open-label , switchover study patient late-onset Pompe disease receive treatment recombinant human acid alpha-glucosidase ( rhGAA ) 48 week longer . Ambulatory patient mild moderate respiratory impairment switch directly receive BMN 701 20 mg/kg IV infusion every week . All participant receive active drug . No dose exist therapy miss - experimental drug start immediately .</brief_summary>
	<brief_title>BMN 701 Phase 3 rhGAA Exposed Subjects With Late Onset Pompe Disease ( INSPIRE Study )</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>Willing able provide write informed consent , nature study explain , prior studyrelated procedure . Diagnosed lateonset Pompe disease base 2 currently previously document GAA gene mutation , endogenous GAA activity &lt; 75 % low limit normal adult range report test laboratory , assess dry blood spot whole blood assay . Has receive prior treatment commercial rhGAA define ALL follow : 1. receive treatment commercial rhGAA ≥ 48 week ( 20 % study population receive treatment ≥ 6 year ) . 2. receive &gt; 80 % schedule treatment prior 48 week ≥ 4 prior 6 scheduled treatment . 3. receive complete last two infusion without drugrelated adverse event result dose interruption . 4. receive last treatment commercial rhGAA ≥ 10 ≤ 31 day prior anticipated initiation treatment BMN 701 . ≥ 18 year age time enrollment study . Sexually active subject must willing use two know effective method contraception participate study least 4 month follow last dose BMN 701 . Females childbearing potential must negative pregnancy test Screening Baseline visit willing additional pregnancy test study . Females consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior Screening , total hysterectomy . Has ≥ 30 % predict upright FVC &lt; 80 % predict upright FVC . Has ≤60 % predict MIP . Is able ambulate ≥75 meter ≤500 meter 6MWT conduct Screening visit ( use assistive device walker , cane , crutch , permit consistent use throughout study ) . Is willing able comply study procedure . Use investigational product investigational medical device within 4 week prior Screening , requirement investigational agent BMN 701 prior completion least first 24 week schedule study assessment . Received investigational medication Pompe disease within prior 12 month . Has diagnosis diabetes and/or currently treat anticipated require treatment hypoglycemic agent course study . Has treat immunosuppressive medication glucocorticosteroids within prior 12 month . Requires noninvasive ventilatory support awake upright position . Has previously enrol study . Breastfeeding Screening plan become pregnant ( self partner ) time study . Concurrent disease , medical condition , extenuate circumstance , opinion Investigator , might compromise subject safety , study treatment compliance completion study , integrity data collect study . Has know hypersensitivity BMN 701 excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>